HK1232226A1 - 抑制bet蛋白的具有间位取代的芳族氨基或醚基的3，4-二氢吡啶并[2，3-b]吡嗪酮 - Google Patents

抑制bet蛋白的具有间位取代的芳族氨基或醚基的3，4-二氢吡啶并[2，3-b]吡嗪酮 Download PDF

Info

Publication number
HK1232226A1
HK1232226A1 HK17105942.9A HK17105942A HK1232226A1 HK 1232226 A1 HK1232226 A1 HK 1232226A1 HK 17105942 A HK17105942 A HK 17105942A HK 1232226 A1 HK1232226 A1 HK 1232226A1
Authority
HK
Hong Kong
Prior art keywords
alkyl
phenyl
unsubstituted
pyrazin
dihydropyrido
Prior art date
Application number
HK17105942.9A
Other languages
English (en)
Chinese (zh)
Inventor
Norbert Schmees
Bernard Haendler
Detlef STÖCKIGT
Richard Alexander Bissell
Richard Alexander BOUGLAS
Ian STEFANUTI
Stephan Siegel
Original Assignee
Bayer Pharma Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma Aktiengesellschaft filed Critical Bayer Pharma Aktiengesellschaft
Publication of HK1232226A1 publication Critical patent/HK1232226A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK17105942.9A 2014-06-18 2015-06-15 抑制bet蛋白的具有间位取代的芳族氨基或醚基的3，4-二氢吡啶并[2，3-b]吡嗪酮 HK1232226A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14173045 2014-06-18
EP14173045.7 2014-06-18
PCT/EP2015/063278 WO2015193219A1 (de) 2014-06-18 2015-06-15 Bet-proteininhibitorische 3,4-dihydropyrido[2,3-b]pyrazinone mit meta-substituierter aromatischer amino- oder ethergruppe

Publications (1)

Publication Number Publication Date
HK1232226A1 true HK1232226A1 (zh) 2018-01-05

Family

ID=50972563

Family Applications (1)

Application Number Title Priority Date Filing Date
HK17105942.9A HK1232226A1 (zh) 2014-06-18 2015-06-15 抑制bet蛋白的具有间位取代的芳族氨基或醚基的3，4-二氢吡啶并[2，3-b]吡嗪酮

Country Status (7)

Country Link
US (1) US20170121322A1 (https=)
EP (1) EP3157919A1 (https=)
JP (1) JP2017519760A (https=)
CN (1) CN106573931A (https=)
CA (1) CA2952526A1 (https=)
HK (1) HK1232226A1 (https=)
WO (1) WO2015193219A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102017005091A1 (de) 2016-05-30 2017-11-30 Bayer Pharma Aktiengesellschaft Substituierte 3,4-Dihydropyrido[2,3-b]pyrazin-2(1H)-one
DE102017005089A1 (de) 2016-05-30 2017-11-30 Bayer Pharma Aktiengesellschaft Substitulerte 3,4-Dihydrochinoxalin-2(1H)-one
BR112020018094A2 (pt) 2018-03-08 2020-12-22 Incyte Corporation Compostos de aminopirazina diol como inibidores de pi3k-¿
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
CA3212314A1 (en) * 2021-03-03 2022-09-09 Bayer Aktiengesellschaft Substituted 3,6-dihydro-2h-1,3,4-oxadiazin-2-ones for the treatment of sarcoma
CN115322128B (zh) * 2022-08-05 2024-06-18 南京师范大学 一种基于烷基卤代物合成C(sp3)-S键的有机硫化合物及其制备方法与应用
WO2025014200A1 (ko) * 2023-07-07 2025-01-16 주식회사 티움바이오 화합물 및 이를 포함하는 약학 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS54645B1 (sr) * 2009-11-05 2016-08-31 Glaxosmithkline Llc Benzodiazepin kao inhibitor bromodomena
AR084070A1 (es) * 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
US9249161B2 (en) * 2010-12-02 2016-02-02 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
HK1211033A1 (en) * 2012-12-20 2016-05-13 Bayer Pharma Aktiengesellschaft Bet-protein-inhibiting dihydroquinoxalinones
WO2014095774A1 (de) * 2012-12-20 2014-06-26 Bayer Pharma Aktiengesellschaft Bet-proteininhibitorische dihydropyridopyrazinone
HK1221721A1 (zh) * 2013-07-09 2017-06-09 Bayer Pharma Aktiengesellschaft Bet蛋白抑制性的改性的二氢喹喔啉酮类化合物和二氢吡啶并吡嗪酮类化合物

Also Published As

Publication number Publication date
EP3157919A1 (de) 2017-04-26
JP2017519760A (ja) 2017-07-20
CA2952526A1 (en) 2015-12-23
WO2015193219A1 (de) 2015-12-23
CN106573931A (zh) 2017-04-19
US20170121322A1 (en) 2017-05-04

Similar Documents

Publication Publication Date Title
HK1211033A1 (en) Bet-protein-inhibiting dihydroquinoxalinones
HK1213899A1 (zh) 抑制bet蛋白的二氢吡啶并吡嗪酮
ES2648876T3 (es) Dihidropirido[3,4-b]pirazinonas sustituidas como inhibidores duales de proteínas BET y quinasas tipo polo
ES2635003T3 (es) Dihidroquinoxalinonas y dihidropiridopirazinonas modificadas inhibidoras de proteína BET
KR101698631B1 (ko) 칼륨 이온 채널 억제제로서의 퀴나졸린
CN104781259B (zh) 抑制bet蛋白的5-芳基三唑并氮杂*
HK1232226A1 (zh) 抑制bet蛋白的具有间位取代的芳族氨基或醚基的3，4-二氢吡啶并[2，3-b]吡嗪酮
CN116323623A (zh) 作为SOS1抑制剂的吡啶并[2,3-d]嘧啶-4-胺
CN105164135A (zh) 4-取代的吡咯并二氮杂卓和吡唑并二氮杂卓
DE102017005091A1 (de) Substituierte 3,4-Dihydropyrido[2,3-b]pyrazin-2(1H)-one
WO2015193228A1 (de) Bet-proteininhibitorische 1,4-dihydropyrido[3,4-b]pyrazinone mit para-substituierter aromatischer amino- oder ethergruppe
WO2015193217A1 (de) Bet-proteininhibitorische dihydropyrido[2,3-b]pyrazinon-derivate mit para-substituierter aromatischer amino- oder ethergruppe
WO2015193229A1 (de) Bet-proteininhibitorische 1,4-dihydropyrido[3,4-b]pyrazinone mit meta-substituierter aromatischer amino- oder ethergruppe
HK1197408A (en) 6h-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepines